TriSalus Q3 Revenue $12.9M; 2026 Guidance Cut to $46-48M as CMS Boosts PEDD Reimbursement
TLSI sits 36% above its 52-week low of $2.2.
Summary
TriSalus grew Q3 revenue 11.3% to $12.9 million but trimmed 2026 guidance to $46-48 million as its expanded sales force ramps slowly. CMS finalized 2027 reimbursement changes that roughly double payment for its main procedure code.
Key Events · Earnings and Guidance · TLSI
-
Q3 Revenue Up 11.3% to $12.9M
TriNav revenue was $12.9 million for the quarter ended September 30, 2026, versus $11.6 million a year earlier, with gross margin rising to 86.2% from 83.5% on lower cost per unit.
-
2026 Guidance Cut to $46-48M
Full-year 2026 revenue guidance was revised to $46 million to $48 million, representing roughly 2% to 6% growth over 2025, after the expanded commercial team ramped slower than anticipated.
-
CMS Raises PEDD Reimbursement for 2027
CMS finalized reassignment of HCPCS C8004 to APC 5194, lifting the national Medicare rate from about $11,794 to about $20,910 per procedure, and set a national payment of about $13,800 for new office-based-lab code G0577 — both effective January 1, 2027.
-
Losses Narrow; $41.1M Cash Left
Operating loss was $7.7 million versus $9.0 million a year ago and adjusted EBITDA loss was $4.7 million versus $5.4 million; cash and equivalents totaled $41.1 million at September 30, 2026.
Analysis · TLSI · Industrial Applications And Services
The near-term numbers disappoint, but the 2027 reimbursement setup is what matters here. Revenue grew 11.3% to $12.9 million and gross margin improved to 86.2%, yet management cut full-year 2026 guidance to $46-48 million — only 2% to 6% growth — and conceded the doubled sales force is ramping slower than planned. Against that, CMS finalized two 2027 payment rules that materially raise reimbursement for the company's core procedures: C8004 jumps from about $11,794 to about $20,910 per case, and new code G0577 pays about $13,800 per office-based lab procedure. Cash of $41.1 million against a $7.7 million quarterly operating loss leaves roughly five quarters of runway before another raise.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSI was trading at $3.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $198.3M. The 52-week trading range was $2.20 to $7.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.